MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VERSUS SELINEXOR-DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0

作者：

Moreau, P. ^{[1
]}

Usmani, S. Z. ^{[2
]}

van de Donk, N. W. C. J. ^{[3
]}

Garfall, A. L. ^{[4
]}

Delforge, M. ^{[5
]}

Oriol, A. ^{[6
,7
]}

Nooka, A. ^{[8
]}

Rosinol, L. ^{[9
]}

Bahlis, N. ^{[10
]}

Otero, Rodriguez P. ^{[11
]}

Martin, T. ^{[12
]}

Diels, J. ^{[13
]}

Van Sanden, S. ^{[13
]}

Pei, L. ^{[14
]}

Ammann, E. ^{[15
]}

Chastain, K. ^{[14
]}

Marshall, A. ^{[15
]}

Slavcev, M. ^{[15
]}

Londhe, A. ^{[16
]}

Krishnan, A. ^{[17
]}

机构：

[1] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, North Holland, Netherlands

[4] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[5] Univ Leuven, Dept Haematol, Leuven, Belgium

[6] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[7] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[8] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[9] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain

[10] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[11] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[12] Univ Calif San Francisco, San Francisco, CA USA

[13] Janssen Pharmaceut NV, Beerse, Belgium

[14] Janssen Res & Dev, Raritan, NJ USA

[15] Janssen Global Serv, Raritan, NJ USA

[16] Janssen Res & Dev, Titusville, NJ USA

[17] City Hope Comprehens Canc Ctr, Irvine, CA USA

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

CO93

引用

下载

页码：S31 / S31

页数：1

共 50 条

[1] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Moreau, Philippe
Usmani, Saad
van de Donk, Niels W. C. J.
Garfall, Alfred
Delforge, Michel
Oriol, Albert
Nooka, Ajay
Rosinol, Laura
Bahlis, Nizar
Rodriguez-Otero, Paula
Martin, Thomas
Diels, Joris
Van Sanden, Suzy
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Marshall, Alexander
Slavcev, Mary
Smit, Jennifer
Londhe, Anil
Krishnan, Amrita
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S182
[2] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Moreau, P.
Usmani, S. Z.
van de Donk, N. W. C. J.
Garfall, A. L.
Delforge, M.
Oriol, A.
Nooka, A.
Rosinol, L.
Bahlis, N.
Rodriguez Otero, P.
Martin, T. G.
Diels, J.
Van Sanden, S.
Pei, L.
Ammann, E.
Chastain, K.
Marshall, A.
Slavcev, M.
Londhe, A.
Krishnan, A.
VALUE IN HEALTH, 2023, 26 (12) : S5 - S6
[3] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Moreau, Philippe
Usmani, Saad Zafar
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Delforge, Michel
Rocafiguera, Albert Oriol
Nooka, Ajay K.
Rosinol, Laura
Bahlis, Nizar J.
Rodriguez-Otero, Paula
Martin, Thomas G.
Diels, Joris
Van Sanden, Suzy
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Slavcev, Mary
Smit, Jennifer
Londhe, Anil
Krishnan, Amrita Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
Bahlis, Nizar J.
Usmani, Saad Zafar
Rosinol, Laura
Krishnan, Amrita Y.
Nooka, Ajay K.
Rocafiguera, Albert Oriol
Delforge, Michel
Garfall, Alfred L.
Van De Donk, Niels W. C. J.
Iguez-Otero, Paula Rodr .
Martin, Thomas G.
Diels, Joris
Van Sanden, Suzy
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Slavcev, Mary
Smit, Jennifer
Londhe, Anil
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha
Hu, Yannan
Leblanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
[7] A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Mol, Isha
Hu, Yannan
LeBlanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
BLOOD, 2023, 142
[8] Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma
Reece, Donna
Diels, Joris
Van Sanden, Suzy
Pei, Lixia
Ammann, Eric
Heuck, Christoph
Kane, Colleen
Londhe, Anil
Peterson, Steve
Chari, Ajai
CURRENT MEDICAL RESEARCH AND OPINION, 2024,
[9] Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Chari, Ajai
Vogl, Dan T.
Gavriatopoulou, Maria
Nooka, Ajay K.
Yee, Andrew J.
Huff, Carol A.
Moreau, Philippe
Dingli, David
Cole, Craig
Lonial, Sagar
Dimopoulos, Meletios
Stewart, A. Keith
Richter, Joshua
Vij, Ravi
Tuchman, Sascha
Raab, Marc S.
Weisel, Katja C.
Delforge, Michel
Cornell, Robert F.
Kaminetzky, David
Hoffman, James E.
Costa, Luciano J.
Parker, Terri L.
Levy, Moshe
Schreder, Martin
Meuleman, Nathalie
Frenzel, Laurent
Mohty, Mohamad
Choquet, Sylvain
Schiller, Gary
Comenzo, Raymond L.
Engelhardt, Monika
Illmer, Thomas
Vlummens, Philip
Doyen, Chantal
Facon, Thierry
Karlin, Lionel
Perrot, Aurore
Podar, Klaus
Kauffman, Michael G.
Shacham, Sharon
Li, Lingling
Tang, Shijie
Picklesimer, Carla
Saint-Martin, Jean-Richard
Crochiere, Marsha
Chang, Hua
Parekh, Samir
Landesman, Yosef
Shah, Jatin
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08): : 727 - 738
[10] A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha
Hu, Yannan
Leblanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (02) : 199 - 207

← 1 2 3 4 5 →